February 2020
Oncostellae received regulatory approval to start a proof of concept study with OST-122 in patients with ulcerative colitis

febrero 21, 2020

---

Oncostellae has received permission from the regulator to start a Phase 2a study with OST-122 in patients suffering from ulcerative colitis….

Read More

11 October 2019
IO4COLON project progress

febrero 21, 2020

---

Investigación industrial para el descubrimiento de nuevos fármacos inmunoterapéuticos en tratamiento de cáncer de colon. El pasado viernes (11 de octubre…

Read More

May 2019
OST-122 has successfully completed a Phase 1b trial in HV and has proved to be GI-restricted and well tolerated up to 1200 mg after multiple dosing

febrero 20, 2020

---

Following a successful randomized, double-blind, placebo-controlled Phase 1a clinical trial in healthy volunteers which was carried out at the Sant Pau…

Read More

10 Dec 2018
GI-restricted Jak3/Tyk2 inhibitor OST-122 well tolerated in clinical phase Ia study

marzo 24, 2019

---

OST-122, a novel, gut-restricted Jak3/Tyk2 inhibitor for the local treatment of gastrointestinal diseases, has completed the first part of a randomized,…

Read More

22 Feb 2019
IO4COLON Project Presentation

febrero 23, 2019

---

Last 22th of February at 12:00 pm was celebrated the Presentation of IO4COLON Project in the CIQUS Research Center We are pleased…

Read More

25-27 Sep 2018
Oncostellae participates at Biospain 2018 in Seville

julio 19, 2018

---

Oncostellae participates at the 2018 Biospain congress that takes place from 25th to 27th of September  2018  in the Fibes Exhibition &…

Read More

14 Feb 2017
Cuatro biotecnológicas gallegas se alían en una plataforma para buscar nuevos fármacos contra el cáncer

febrero 14, 2016

---

GalChimia, AMSLab, Oncostellae y Nanogap presentan Neogalfarma, que aspira a diseñar, sintetizar y evaluar biológicamente nuevas moléculas antitumorales Cuatro empresas gallegas…

Read More